Provectus Biopharmaceuticals Reports First Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Provectus Biopharmaceuticals Reports First Quarter Financial Results
May 8, 2015 8:05 AM EDT
Provectus Biopharma (NYSE: PVCT) provided the market with a business update in its quarterly investor conference call held on Thursday, May 7, 2015, that addresses several matters in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. A webcast and transcript of the call are available at http://www.pvct.com/inthenews.html?article=20150507.2
During the first quarter, Provectus opened recruitment for its phase 2 mechanism of action trial of PH-10 for the treatment of mild to moderate psoriasis. The purpose of the trial is to study the safety and... More
May 7, 2015 6:24 AM EDT
Provectus Biopharma (: PVCT) reported Q1 EPS of ($0.02), versus ($0.04) reported last year.
Plan of Operation
We have implemented our integrated business plan, including execution of the current and next phases in clinical development of our pharmaceutical products and continued execution of research programs for new research initiatives.
Our current plans include continuing to operate with our four employees during the immediate future,... More
